The assessment of suicidality in psychiatric trials: a protocol for a scoping review Authors: Pascal Faltermeier, Sophie Juul, Faiza Siddiqui, Delal Yücel, Mark Horowitz, Joanna Moncrieff, Christian Gluud, Janus Christian Jakobsen Published: 2025 ABSTRACT AbstractIntroductionSuicide is one of the leading causes of death worldwide, especially in patients with mental health disorders. Suicidality is an important outcome for patients in psychiatric randomised clinical trials. The aim of this scoping review is to assess whether and how psychiatric trials assess suicidal ideation, suicide attempts, and suicides.MethodsThis is a protocol for a scoping review. We will conduct a search of high-impact journals for randomised clinical trials published since January 2022 that include mental health patients, irrespective of the intervention type. We will assess if and how psychiatric trials assess suicidal ideation, suicide attempts, and suicides.DiscussionThis scoping review will be the first to examine how suicidality is assessed in contemporary randomised clinical trials. In combination with the PIO-Psych Initiative, this scoping review will ultimately guide future researchers in selecting patient-important outcomes and inform clinical research practice. However, the focus on high-impact journals may limit the generalisability of the findings.Scoping review registrationThis scoping review is part of a project that has been prospectively registered on the COMET website (https://comet-initiative.org/Studies/Details/3125).Keywords: Suicide, Suicide risk, Transdiagnostic mental health, Scoping review Introduction Choosing the primary outcome is a vital part of planning clinical trials [1, 2]. The choice influences the external validity [1], and the outcome must be important to patients [1, 2]. Psychiatric trials routinely employ symptom scales (e.g. Beck Anxiety Inventory (BAI) [3], Hamilton Depression Rating Scale (HDRS) [4], and the Positive and Negative Syndrome Scale (PANSS) for schizophrenia [5]) as primary outcomes. Symptom scales do, however, have several methodological issues. One problem is establishing a minimal important difference (MID)—“the smallest difference in score in the domain of interest which patients perceive as beneficial and which would mandate, in the absence of troublesome adverse effects and excessive cost, a change in the patient’s management” [6]. Established MIDs are often too lenient or differ heavily depending on the method used to establish them [7, 8]. This and several other issues have been described previously [9, 10] and are summarised in Table 1. Table 1Methodological issues of the use of symptom scales as primary outcomesMethodological issuesDescriptionMinimal important differenceThe MID is often unclear [11–13]. If an MID is established, the meaning is often still unclear and the resulting estimates often uncertain [8, 14–16]Psychometric challengesPsychometric challenges with symptom scales, like inconsistent item validity, severity, and reliability, can complicate score interpretation, as seen with the Hamilton Depression Rating Scale, which may mask severe symptoms when others improve, prompting a need for re-evaluation in clinical trials [12, 13]SubjectivitySymptom scales are often subjective which introduces bias, especially in unblinded trials and in cases of unblinding due to adverse events [17–19]Missing dataSymptom scales show a high rate of missing data. This can introduce bias and undermine the validity of the trial [20]Unclear long-term effectsSymptom scales often emphasise short-term changes, while overlooking the potential negative long-term effects [21] Methodological issues of the use of symptom scales as primary outcomes Despite these limitations, symptom scales often serve as the basis for clinical guidelines and impact the treatment of millions of patients worldwide [22–24]. An alternative to symptom scales is hard outcomes (e.g. employment status, hospitalisations, or suicides) [25]. Compared with symptom scales, hard outcomes have significantly fewer downsides. They are directly important to patients, less affected by a lack of blinding, and have fewer missing data [20, 25, 26]. Suicide as an outcome Suicide is a hard binary outcome and is the second leading cause of death in young adults and one of the leading causes of death in the age groups between 10 and 64 years [27–29]. The risk of suicide is even higher in patients with mental disorders [30–34]. The suicide mortality rate ratio is 11.82 for patients with any mental health disorder and 14.30 for patients with a mood disorder compared to those without a diagnosis [30]. The mortality rate ratio of suicides is significantly higher than the mortality rate ratios for all causes of death (2.53 among patients with any mental health disorder and 1.92 among patients with a mood disorder) compared to those without a diagnosis [30]. Another study showed excess mortality due to suicides ranging from ninefold for substance abuse disorder to 77-fold in affective disorders [31]. In a study on patients with a diagnosis of schizophrenia, suicides were the leading cause of death [35]. Suicide is also one of the main reasons for excess life years lost for those with a diagnosis of any mental disorder [27, 30, 34]. Suicide risk is influenced by a multitude of factors, such as biological predisposition, specific personality traits, comorbidities, and social and environmental factors [36]. Suicide risk in psychiatric patients is commonly assessed via questionnaires and psychometric scales such as the Columbia-Suicide Severity Rating Scale or the Scale for Suicidal Ideation [37, 38]. Multiple reviews have assessed the predictive value of suicidal ideations scale, and no evaluated scale fulfilled the requirements for sufficient diagnostic accuracy [39–41]. The World Health Organization recently recommended prioritising suicide prevention in patients with mental disorders [42]. As suicide attempts and suicides are relatively common in psychiatric patients [43, 44], it is feasible to conduct randomised clinical trials with suicide as a primary outcome, with sample sizes corresponding to those in non-psychiatric trials [9]. Suicide attempts and suicides can be accessed via various registries in some countries, further reducing the risk of missing data. Previous articles have highlighted how important the assessment of suicidality in clinical trials is and proposed ways to accomplish this [45–47]. One review showed that suicidal patients are commonly excluded from antidepressant trials, which makes it impossible to assess whether the interventions are safe for suicidal patients [48]. No prior review has evaluated whether and how suicide risk, suicide attempts, and suicides are assessed in clinical trials. Suicidality is an important primary outcome to consider in psychiatric trials. The aim of this scoping review is to assess whether and how clinical trials assess suicide risk, suicide attempts, or suicides. Methods This present protocol is part of the transdiagnostic core outcome set for mental health disorders in adults: the Patient Important Outcomes in Psychiatry (PIO-Psych) Initiative. The project was prospectively registered in the COMET database on May 17, 2024 [49]. Search strategy An information specialist will upload to Covidence all articles published between January 2022 and August 2024 in 18 mental health scientific journals. The journals were selected either based on their journal impact factor being high or based on their diagnostic specialty to cover a broad range of mental health disorders. Trials will be included irrespective of their language. The included journals will be: World Psychiatry: https://www.wpanet.org/english World Psychiatry: https://www.wpanet.org/english Lancet Psychiatry: https://www.thelancet.com/journals/lanpsy/home Lancet Psychiatry: https://www.thelancet.com/journals/lanpsy/home JAMA Psychiatry: https://jamanetwork.com/journals/jamapsychiatry JAMA Psychiatry: https://jamanetwork.com/journals/jamapsychiatry Psychotherapy and Psychosomatics: https://karger.com/pps Psychotherapy and Psychosomatics: https://karger.com/pps American Journal of Psychiatry: https://ajp.psychiatryonline.org/ American Journal of Psychiatry: https://ajp.psychiatryonline.org/ British Journal of Psychiatry: https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry British Journal of Psychiatry: https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry Journal of Anxiety Disorders: https://www.sciencedirect.com/journal/journal-of-anxiety-disorders Journal of Anxiety Disorders: https://www.sciencedirect.com/journal/journal-of-anxiety-disorders Schizophrenia Bulletin: https://academic.oup.com/schizophreniabulletin Schizophrenia Bulletin: https://academic.oup.com/schizophreniabulletin Journal of Affective Disorders: https://www.sciencedirect.com/journal/journal-of-affective-disorders Journal of Affective Disorders: https://www.sciencedirect.com/journal/journal-of-affective-disorders Journal of Personality Disorders: https://www.guilford.com/journals/Journal-of-Personality-Disorders/Krueger-Oldham/0885579X Journal of Personality Disorders: https://www.guilford.com/journals/Journal-of-Personality-Disorders/Krueger-Oldham/0885579X International Journal of Mental Health and Addiction: https://link.springer.com/journal/11469 International Journal of Mental Health and Addiction: https://link.springer.com/journal/11469 Bipolar Disorders: https://onlinelibrary.wiley.com/journal/13995618 Bipolar Disorders: https://onlinelibrary.wiley.com/journal/13995618 Frontiers in Psychology: https://www.frontiersin.org/journals/psychology Frontiers in Psychology: https://www.frontiersin.org/journals/psychology Journal of Applied Psychology: https://www.apa.org/pubs/journals/apl Journal of Applied Psychology: https://www.apa.org/pubs/journals/apl Psychological Bulletin: https://www.apa.org/pubs/journals/bul Psychological Bulletin: https://www.apa.org/pubs/journals/bul Annual Review of Psychology: https://www.annualreviews.org/content/journals/psych Annual Review of Psychology: https://www.annualreviews.org/content/journals/psych International Journal of Eating Disorders: https://onlinelibrary.wiley.com/journal/1098108X International Journal of Eating Disorders: https://onlinelibrary.wiley.com/journal/1098108X Nature Human Behavior: https://www.nature.com/nathumbehav/ Nature Human Behavior: https://www.nature.com/nathumbehav/ Selection of studies Two review authors will independently screen titles and abstracts. We will retrieve all relevant full-text study reports/publications. Two review authors will independently screen the full texts and record reasons for excluding the ineligible studies. The same two review authors will resolve any disagreements through discussion, or if necessary, they will consult a third author (JCJ). Types of studies We will include randomised clinical trials regardless of trial design and setting (e.g. inpatient, outpatient, or primary care settings). We will not include prevention trials of healthy participants or trials primarily including somatic patients. Types of participants We will include trials assessing any mental health disorder in adults, such as major depressive disorder, bipolar disorder, anxiety disorders, obsessive-compulsive disorder, eating disorders, personality disorders, post-traumatic stress disorder, and schizophrenia. Types of interventions and comparators We will include any randomised clinical trial irrespective of the intervention and comparator groups. Data extraction and management Two review authors will independently extract data from included trials in a predefined form. Disagreements will be resolved by discussion with a third author (JCJ). Each trial will be named after the first author and year of the primary publication, and all secondary publications will be classified under that name. Trial characteristics We will extract the following data: protocol available (Y/N); trial design (parallel, factorial, or crossover); countries; primary sponsor geographical region; setting (inpatient/outpatient); diagnosis; inclusion and exclusion criteria; exclusion of suicidal patients (Y/N); maximum follow-up time. Participant characteristics We will extract the following data: number of randomised participants; age range (inclusion criteria), sex, and gender. Intervention characteristics We will extract the following data: type of intervention. Control characteristics We will extract the following data: type of control intervention. Outcomes We will extract if and how the following outcomes were assessed: Suicide (yes/no) Suicide (yes/no) Suicide attempt (yes/no) Suicide attempt (yes/no) Suicide risk (yes/no) (including suicidality, suicidal ideation, and suicidal behaviour) Suicide risk (yes/no) (including suicidality, suicidal ideation, and suicidal behaviour) Suicide-related outcomes like suicide risk or suicidality are often not properly defined, and the terminology lacks international consensus [50]. Data synthesis We will group all interventions and control interventions into the following categories: combination therapy, neurostimulation, pharmacological interventions, physical activity, psychosocial interventions, psychotherapeutic interventions, and other interventions. We will group all diagnoses into the following categories: addiction disorders, affective disorders and anxiety disorders, eating disorders, neurodevelopmental disorders, personality disorders, post-traumatic stress disorders, psychosis and schizophrenia spectrum disorders, sleeping disorders, other disorders, and transdiagnostic. The assessment of suicide and suicide attempts will be narratively reported. The assessment of suicide risk will be divided into the following categories: self-report or clinician-rated and continuous or binary. We will report on the percentage of trials assessing any suicide-related outcome (suicide, suicide attempt, or suicide risk). We will also report the number of trials that report on each individual outcome. We will descriptively report the difference in the assessment of suicide-related outcomes in the following areas: primary diagnosis, type of intervention, and journal. Patient and public involvement and ethical considerations Patients or the public were not involved in the design of this protocol. We are currently reaching out to several patient organisations to involve patients in the future conduct, reporting, and dissemination plans of the Patient Important Outcomes in Psychiatry Initiative. We plan to discuss and interpret our findings with the patients involved. We will only use aggregate data, and no patient will be involved during data collection. All included trials will have obtained the required ethical approval; therefore, ethical approval or oversight is not necessary for this review. Discussion The scoping review will aim to investigate if and how randomised clinical trials assess suicide risk, suicide attempts, and suicide. The strengths of this scoping review include its predefined methodology and high degree of clinical relevance. The limitations of this scoping review will be that it is limited to trials published between 2022 and 2024 and might omit a trend showing an increased or decreased use of suicide as an outcome. Furthermore, the scoping review mainly includes high-impact-factor journals, which may reduce the generalisability of the results and fail to accurately reflect the reality of outcome selection in randomised clinical trials. We chose these restrictions to ensure the feasibility of this scoping review while preserving the quality of the included evidence. Trials published in high-impact-factor journals are likely to reflect what is considered best practice in the field and therefore likely to yield higher quality data. With this review, we want to summarise the use of suicidality as an outcome in clinical trials in mental health patients. We hope that highlighting the current heterogeneity will lead to a standardised taxonomy in future trials. This could promote suicidality as an outcome for future clinical trials. To further incentivise this, ethical review boards and funding agencies should require the inclusion of suicidality as an outcome in suitable trials as a criterion for trial approval. Acknowledgements The development of this protocol has been supported by The Copenhagen Trial Unit. The literature search will be conducted by Sarah Louise Klingenberg. Data statement Not applicable for this protocol article. Abbreviations Beck Anxiety Inventory Hamilton Depression Rating Scale Positive and Negative Syndrome Scale Minimal important difference Patient Important Outcomes in Psychiatry Initiative Authors' contributions PF and JCJ wrote up the first manuscript draft. SJ, FS, DY, MH, JM, and CG significantly contributed to the writing and commented on the manuscript. All authors read and approved the final version of the manuscript. Funding This protocol has not received any funding. Data availability Full syntax of all statistical analyses will be published as supplementary material. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests JM and MAH are collaborating investigators on the NHMRC- and MRFF-funded RELEASE and RELEASE+ trials in Australia investigating hyperbolic tapering of antidepressants. MAH is a co-founder of Outro Health, a digital clinic which aims to help people who wish to stop no longer needed antidepressant medication in North America. MAH has received honoraria for lectures on deprescribing from NHS Trusts, Washington University, and the University of Arizona. MAH receives royalties for the Maudsley Deprescribing Guidelines. JM was a co-investigator on a National Institute of Health Research (NIHR) funded study exploring methods of antidepressant discontinuation (REDUCE) and the chief investigator on the RADAR trial of antipsychotic reduction and discontinuation funded by the NIHR. She collects royalties from three books on psychiatric drugs. None of the other authors had any competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Full syntax of all statistical analyses will be published as supplementary material.